Does Allopurinol Shorten Your Life? Long-Term Safety Explained

Many people who are newly prescribed allopurinol wonder whether taking it for years could affect their life expectancy or overall health. It is understandable to have concerns about starting a prescription-only medicine for long-term use, particularly if you have heard conflicting information online or from other people with gout. 

This article explains what the evidence shows about allopurinol, life expectancy and long-term safety. It covers how allopurinol works as a urate-lowering therapy, what clinical research says about all-cause mortality and cardiovascular safety, why treating gout and hyperuricemia matters, and the genuine risks associated with treatment. It also provides an evidence-based answer to help offer patient reassurance and explain why allopurinol remains one of the most widely prescribed medicines for gout. 

As an online prescription service, UK Meds aims to help patients make informed decisions using reliable, evidence-based information.

In One Sentence:

Current evidence shows that allopurinol does not shorten life, with UK studies finding no increased risk of death, no evidence that it shortens life, and even a lower risk in kidney disease for some patients when taken as prescribed, reviewed regularly and used to reduce the long-term health risk of untreated gout.

Key Takeaways

• Does allopurinol shorten your life? 

Current evidence shows that allopurinol does not shorten life, and there is no increased risk of all-cause mortality when it is used appropriately.

• Is it safe long term? 

Yes. Allopurinol has more than 50 years of use, is well studied and is considered safe for long-term treatment in most people.

• What is the real risk? 

Under-treated gout can lead to joint damage, kidney damage and heart disease, making uncontrolled gout a greater long-term concern than allopurinol itself.

• Does it have serious side effects and who is most at risk? 

A severe allergic skin reaction is rare, usually develops during the first few weeks of treatment and is more likely in people with the HLA-B*58:01 gene variant.

• Can you take it for life and should you stop if you feel fine? 

Allopurinol is often used as lifelong preventive treatment, and you should not stop taking it without medical advice because urate rebound can increase the risk of future gout flares.

What does the clinical evidence say about allopurinol and lifespan?

The best available clinical evidence shows that allopurinol is not associated with a higher risk of death and may even be linked to improved outcomes in some higher-risk groups.

When researchers assess whether a medicine affects lifespan, they often examine all-cause mortality, which measures deaths from any cause rather than focusing on one specific illness. This provides one of the clearest ways to understand whether a treatment is associated with harm over time.

Keele University Study

The current clinical evidence is reassuring for people taking allopurinol to manage gout. A systematic review led by researchers at Keele University combined data from multiple studies and found no significant association between allopurinol use and all-cause mortality. In fact, the results showed a non-significant trend toward lower risk, suggesting that patients taking allopurinol were no more likely to die than those who were not receiving the medicine, and may even have experienced improved outcomes overall [1].

UK Cohort Study

Further reassurance comes from a UK cohort study in gout and kidney disease, published in the Annals of Internal Medicine. Researchers followed people with gout and chronic kidney disease and found that allopurinol initiation was associated with a lower risk of death compared with people who did not begin treatment [2]. This finding is particularly important because chronic kidney disease is already linked with an increased risk of serious health problems, making safe urate-lowering treatment especially valuable.

ALL-HEART Trial

Questions have also been raised about whether allopurinol affects the heart. The ALL-HEART trial examined people with ischaemic heart disease who did not have gout. While the study found no cardiovascular benefit from prescribing allopurinol in this group, it also showed that the medicine was well tolerated over several years and identified no excess harm related to treatment [3].

FAST Trial

Additional reassurance comes from the FAST trial, which was required by the European Medicines Agency to compare the long-term cardiovascular safety of febuxostat with allopurinol. The study found that febuxostat was not inferior to allopurinol for major cardiovascular events or all-cause mortality, reinforcing allopurinol's role as the long-standing cardiovascular safety benchmark for urate-lowering therapy [4].

Randomised Trial

Some observational evidence on allopurinol and cardiovascular risk has suggested that patients taking allopurinol for longer than six months at an adequate dose may have a lower risk of cardiovascular disease. However, researchers also noted that stronger randomised trials are still needed before firm conclusions can be drawn about this possible protective effect [5].

Taken together, the weight of evidence from systematic reviews, UK population studies and large clinical trials consistently shows that allopurinol is not associated with an increased risk of death. For many people living with gout, the evidence instead supports its long-term safety when prescribed appropriately and monitored regularly.

"Many patients are convinced that allopurinol is dangerous because it is taken for many years, but the actual data tell a different story. It is one of the most studied medicines in rheumatology and has been in use since the 1960s. The strongest UK evidence shows no increased risk of death and even suggests a lower risk in people with kidney disease who begin appropriate treatment."

Why is untreated gout the bigger risk to your health?

Untreated gout is the real long-term threat because ongoing high serum urate levels allow crystals to build up, increasing the risk of lasting joint damage, kidney disease and other serious health problems.

Serum Urate

Serum urate that remains above the target level allows monosodium urate crystals to continue forming and depositing within joints and surrounding tissues. Although gout attacks often come and go, crystal joint deposition continues between flares if urate levels remain high.

Over time, this process can lead to lasting joint damage, bone erosion, chronic gouty arthritis and the formation of tophi, which are visible deposits of urate crystals beneath the skin. These changes can permanently affect mobility and quality of life if gout is left untreated.

Chronic Kidney Disease

The effects are not limited to the joints. Gout is also linked with a higher burden of chronic kidney disease (CKD), cardiovascular disease, high blood pressure, hypertension and type 2 diabetes. These conditions often occur together, a pattern known as comorbidity clustering, making effective gout management an important part of protecting long-term health.

Research shows that gout affects around 1 in 40 UK adults, or approximately 2.5% of adults, yet treatment remains suboptimal. Despite clear recommendations, only around one third of eligible patients are prescribed allopurinol and only about 40% reach the recommended serum urate target through appropriate dose titration to target [1].

Achieving the recommended serum urate target helps dissolve existing crystals over time while preventing new ones from forming. An England-wide study also found that although urate-lowering therapy was associated with a temporary increase in hospitalisation during the first six months, likely because of mobilisation flares as crystals begin to dissolve, long-term outcomes improved substantially when patients achieved a serum urate concentration below 360 micromol/L [6].

This evidence highlights that undertreated gout is a far greater concern than long-term allopurinol treatment itself. Taking the medicine consistently and adjusting the dose until the target urate level is reached offers the best opportunity to prevent future complications affecting the joints, kidneys and cardiovascular system.

"The danger runs the other way. Gout that is left to simmer for years allows permanent damage to build up. Taking allopurinol properly, bringing urate down to target and keeping it there helps protect the joints and kidneys, providing long-term protection rather than creating long-term harm."

What are the real risks of allopurinol?

For most people, allopurinol is generally very safe, but like any medicine it has recognised risks that should be understood before treatment begins.

After more than 50 years of clinical use, allopurinol has a well-established safety profile and remains the first choice urate-lowering treatment for most people with gout. Millions of patients worldwide have taken the medicine successfully for many years, providing doctors with extensive evidence about its long-term safety.

Most people experience no serious problems while taking allopurinol. Some people may develop mild adverse effects, such as stomach upset, diarrhoea or a mild skin rash, particularly when first starting treatment. These symptoms are often temporary, but they should still be discussed with a healthcare professional if they persist.

The most important point to remember is that the medicine's risk profile is well understood. While there is a rare severe allergic reaction that can occur, particularly during the first weeks and months of starting treatment, this affects only a very small proportion of patients. Healthcare professionals reduce this risk by starting with an appropriate dose, considering kidney function and monitoring patients during the early stages of treatment.

Evidence from a meta-analysis of allopurinol's safety found that allopurinol had an adverse-event rate similar to comparable treatments. The researchers also reported that no deaths in the analysed clinical trials were considered to be directly related to the medicine itself [7].

For the vast majority of people, the health benefits of controlling uric acid levels and preventing gout complications greatly outweigh the small risk of serious side effects.

Allopurinol and Severe Skin Reactions

Severe cutaneous adverse reactions to allopurinol are rare but require immediate medical attention if warning signs develop.

The most serious complication associated with allopurinol is a group of conditions known as severe cutaneous adverse reactions (SCARs). These include Stevens-Johnson syndrome, toxic epidermal necrolysis, allopurinol hypersensitivity syndrome and DRESS, which stands for Drug Reaction with Eosinophilia and Systemic Symptoms.

Although these conditions are very uncommon, recognising them early is extremely important because prompt treatment improves outcomes.

Timing

The highest risk is during the first 8 to 9 weeks after starting allopurinol.

Most severe reactions occur soon after treatment begins rather than after many years of successful use. This is why healthcare professionals pay particular attention to patients during the first two months of therapy. Someone who has taken allopurinol safely for years is much less likely to suddenly develop one of these reactions.

Genetics

The HLA-B*58:01 gene variant substantially increases the risk of severe skin reactions in certain populations.

Research in pharmacogenomics has identified the HLA-B*58:01 gene variant as one of the strongest known genetic risk factors for allopurinol hypersensitivity. The variant is considerably more common in some East and Southeast Asian populations, where studies estimate a prevalence of around 12 to 20%, than in people of European ancestry [8].

Because of this difference, genetic testing may be considered in some higher-risk ancestral groups before treatment begins.

Starting Dose and Kidney Function

Starting with a low dose and adjusting treatment according to kidney function helps reduce the risk of serious reactions.

Healthcare professionals generally follow a "start low, go slow" approach when prescribing allopurinol. The starting dose is often lower for people with renal impairment, allowing the medicine to be increased gradually while monitoring how well it is tolerated.

The NHS also advises that people with reduced kidney function may require a lower dose and careful monitoring throughout treatment [9].

Important safety point

Any new skin rash while taking allopurinol should be taken seriously until assessed by a healthcare professional.

Early red-flag warning signs may include:

• A widespread skin rash

• Fever

• Blistering

• Mucosal involvement, including mouth and eye sores

• Feeling generally unwell

The NHS advises stopping allopurinol and seeking urgent medical advice if a rash develops because this may be the first sign of a serious allergic reaction. Patients should not restart the medicine unless they have been specifically advised to do so by their healthcare professional.

It is worth remembering that these reactions are rare, but understanding the symptoms allows people to act quickly if they occur.

Allopurinol Versus Febuxostat: Which is safer?

Allopurinol remains the preferred first-line urate-lowering medicine for most people, including many with heart disease.

Both allopurinol and febuxostat reduce uric acid levels by inhibiting xanthine oxidase, making them effective urate-lowering medicines. However, their safety profiles have been examined carefully over the past decade, particularly in people with cardiovascular disease.

Concerns about febuxostat largely arose following the CARES trial comparing febuxostat and allopurinol, which studied people with gout with existing heart disease. While the primary cardiovascular outcomes were similar, researchers found higher mortality with febuxostat, including both all-cause mortality and cardiovascular mortality, leading to regulatory warnings in several countries [10].

More recent evidence from the FAST trial provided additional reassurance regarding febuxostat by finding no excess risk compared with allopurinol. Regulatory caution remains in place, particularly for patients with significant cardiovascular disease.

Current guidance from the MHRA and NICE, including NG219, continues to recommend allopurinol as the preferred first-line choice for most people with gout. NICE specifically recommends it as the first-line urate-lowering treatment for people with major cardiovascular disease, including those with a previous heart attack or stroke, unless there is a reason it cannot be used [11].

This long history of safe use means that allopurinol remains the well-established benchmark option against which newer urate-lowering medicines continue to be compared.

"We never downplay the hypersensitivity risk because it is a serious reaction, but it is also rare and heavily concentrated in the first couple of months after treatment begins. Starting with a low dose, checking kidney function and making sure patients know which rash to act on helps make allopurinol as safe in everyday practice as it appears in the clinical evidence."

How is allopurinol dosed and monitored?

Allopurinol works best when it is started gradually, increased carefully and monitored regularly to achieve the recommended serum urate target.

Healthcare professionals usually follow the principle of start low, go slow when beginning allopurinol dosing. This approach helps reduce the likelihood of triggering a gout flare while also lowering the risk of adverse reactions during the first weeks of treatment.

The usual starting dose is 100mg or less, with an even lower starting dose often recommended for people with kidney disease or significantly reduced kidney function. Rather than prescribing a high dose immediately, clinicians gradually increase treatment according to the individual's response.

Titration To Target

The dose is increased in steps until the target serum urate level is reached.

Rather than using the same dose for every patient, allopurinol is adjusted through titration, with the dose increased in steps approximately every 4 weeks. During this process, blood urate tests help measure treatment success.

For most people, the recommended serum urate target is below 360 micromol/L. People with tophi or frequent flares may benefit from a lower target of below 300 micromol/L to encourage faster crystal dissolution.

Flare-Prevention Cover

Preventing early flares helps people continue treatment successfully.

Ironically, allopurinol can temporarily increase gout flares when treatment first begins because falling urate levels disturb existing crystal deposits. These are known as mobilisation flares.

To reduce this risk, healthcare professionals often prescribe flare prophylaxis using colchicine, an NSAID or another suitable anti-inflammatory medicine during the first 3 to 6 months of treatment.

Continue Treatment During Flares

A gout flare does not usually mean allopurinol should be stopped.

If a flare develops after treatment has started, patients are generally advised not to stop during a flare. Instead, the flare is treated separately while allopurinol continues working to lower long-term urate levels.

Stopping treatment each time symptoms appear can slow progress towards the target urate level and increase the likelihood of future attacks.

Long-Term Monitoring

Regular reviews help ensure treatment continues working effectively.

For many people, allopurinol becomes lifelong treatment because it prevents crystals from building up again after the target urate level has been achieved.

Once stable, annual urate monitoring and routine medication reviews help confirm that treatment remains effective. Recommendations from the BNF and NICE support ongoing monitoring, dose adjustment where needed and continued treat-to-target management to provide the greatest long-term benefit for people living with gout.

Frequently Asked Questions

Can you take allopurinol for life?

Yes, allopurinol is commonly used as a lifelong preventive treatment for people with gout who need ongoing control of their serum urate levels.

For many people, gout is a long-term condition rather than something that can be permanently cured. Although symptoms may disappear once allopurinol has lowered serum urate to the target level, the underlying tendency to produce excess uric acid often remains.

Continuing lifelong preventive treatment helps prevent new urate crystals from forming while allowing existing crystals to dissolve over time. If treatment is continued after reaching the target serum urate level, the risk of future gout flares, joint damage and crystal build-up remains much lower than if treatment is stopped.

Your prescriber will review your treatment regularly to make sure it continues to be appropriate for your individual circumstances.

What happens if you suddenly stop taking allopurinol?

Stopping allopurinol suddenly can allow serum urate levels to rise again, increasing the risk of future gout flares.

One of the most important reasons to continue treatment is to avoid serum urate rebound. When stopping allopurinol, uric acid levels can increase again, allowing new crystals to form.

Over time, gout flares return more frequently for many people, placing the joints at risk of further crystal deposition and increasing the possibility of damage. Higher urate levels may also leave the kidneys at risk, particularly in people who already have reduced kidney function.

You should not stop without medical advice, even if you have not experienced a gout attack for several months or years. Likewise, healthcare professionals generally advise that you do not stop during a flare, as continuing allopurinol while treating the flare separately offers the best chance of achieving long-term control.

Does allopurinol affect your liver or kidneys?

Allopurinol can affect liver enzymes in a small number of people, but careful monitoring helps ensure it is used safely.

Although allopurinol is processed by the body in ways that involve the kidneys, it is widely used in people with reduced kidney function when prescribed appropriately.

People with renal impairment usually receive a lower dose, particularly when treatment begins, with dose adjustments based on blood test results and serum urate levels. Regular blood tests may include checks of kidney function and liver enzymes, especially when treatment is first started, or doses are increased.

According to NHS guidance, careful dose adjustment and monitoring help support the safe use of allopurinol in people with reduced kidney function [9].

Is allopurinol bad for your heart?

Current evidence suggests allopurinol has a reassuring heart safety profile and remains the preferred urate-lowering option for many people with heart disease.

Several large clinical trials have examined allopurinol and heart safety. While studies have not shown that it prevents cardiovascular disease, they have also found no excess heart harm when it is used appropriately.

NICE continues to recommend allopurinol as the preferred urate-lowering option for many people with heart disease, reflecting the reassuring evidence from large trials and many years of clinical experience [11].

For patients who require urate-lowering therapy, allopurinol remains a reassuring choice supported by long-term safety data.

How long does allopurinol take to work?

Allopurinol begins lowering urate levels within weeks, but the full benefits develop over several months.

The allopurinol onset of action starts soon after treatment begins, as it lowers urate within weeks. However, dissolving crystal deposits already present in the joints takes considerably longer.

Because of this crystal dissolution, some people continue to experience flares for months, even though the medicine is working as intended. This is why a flare-prevention medicine, such as low-dose colchicine or another suitable anti-inflammatory treatment, is often prescribed alongside allopurinol during the first few months.

Understanding this expected effect helps patients continue treatment rather than assuming the medicine is not working.

Can I take allopurinol with my other medicines?

Allopurinol can interact with some medicines, so your prescriber should always know everything you are taking.

Most medicines can be taken safely with allopurinol, but there are important allopurinol drug interactions that healthcare professionals check before prescribing.

Particular care is needed with azathioprine and mercaptopurine, as allopurinol can significantly increase the effects of these medicines. If they need to be used together, substantial dose adjustments and specialist supervision are required.

Always provide your healthcare professional with a complete prescriber medicines list, including prescription medicines, over-the-counter products and herbal supplements. This helps support safe co-prescribing and reduces the likelihood of avoidable interactions.

Final Thoughts From Our Clinical Team

“The best available evidence shows that allopurinol does not shorten life. After over half a century of use, it remains one of the most studied medicines used to treat gout. The best UK data show no increased risk of death, while some studies even suggest a lower risk in kidney disease among people who begin appropriate treatment. By comparison, untreated gout remains a significant concern, and under-treatment in the UK continues to leave many people at risk of preventable joint and kidney damage.

Like all medicines, allopurinol is not completely without risk. A severe allergic reaction is a genuine but rare risk, particularly during the first few months of treatment. Following a low starting dose, carrying out kidney function checks where appropriate and knowing to act quickly on any rash all help reduce this risk even further.

For most people, the aim of treatment is to bring urate to target and maintain lifelong control of gout, rather than simply treating individual flares. Decisions about starting, adjusting or stopping treatment should always take account of your individual kidney function, other medicines and your wider medical history.

Do not start or stop treatment based on an article alone. If you have concerns about allopurinol, speak to your prescriber, who can provide advice tailored to your personal circumstances and help you make an informed decision about your treatment.”

Sources

[1] Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta‐Analysis

[2] Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease: A Population-Based Cohort Study: Annals of Internal Medicine

[3] Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial - The Lancet

[4] Articles Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

[5] Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis | PLOS One

[6] Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England | Rheumatology | Oxford Academic

[7] Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis | Rheumatology International | Springer Nature Link

[8] A systematic review and network meta-analysis of cardiovascular safety of benzbromarone compared to febuxostat and allopurinol in patients with gout

[9] Allopurinol: a medicine to treat gout - NHS

[10] Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout | New England Journal of Medicine

[11] Recommendations | Gout: diagnosis and management | Guidance | NICE